{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:21:55Z","timestamp":1768033315482,"version":"3.49.0"},"reference-count":19,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0620","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:08:37Z","timestamp":1767823717000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Mutational Burden\u2013High Intrahepatic Cholangiocarcinoma Presenting with Solitary Brain Metastasis: A Case of Precision Oncology"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3401-6188","authenticated-orcid":false,"given":"Takahiro","family":"Maehata","sequence":"first","affiliation":[{"name":"Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-8013","authenticated-orcid":false,"given":"Yuta","family":"Ushida","sequence":"additional","affiliation":[{"name":"Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoriko","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toyota Kosei Hospital, Toyota, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Surgery, Toyota Kosei Hospital, Toyota, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383: 2168\u201379.","DOI":"10.1016\/S0140-6736(13)61903-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2019; 28: 587\u201399.","DOI":"10.1016\/j.soc.2019.06.002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Frega G, Garajov\u00e1 I, Palloni A, et al. Brain metastases from biliary tract cancer: a monocentric retrospective analysis of 450 patients. Oncology 2018; 94: 7\u201311.","DOI":"10.1159\/000479929"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Takada K, Kubo T, Kikuchi J, et al. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study. Front Oncol 2022; 12: 988527.","DOI":"10.3389\/fonc.2022.988527"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Falkson SR, Zhang K, Bhambhvani HP, et al. Biliary cancer brain metastases: a multi-institution case series with case reports. J Gastrointest Oncol 2022; 13: 822\u201332.","DOI":"10.21037\/jgo-21-818"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Takano S, Yoshii Y, Owada T, et al. Central nervous system metastasis from gallbladder carcinoma--case report. Neurol Med Chir (Tokyo) 1991; 31: 782\u20136.","DOI":"10.2176\/nmc.31.782"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mimatsu K, Oida T, Kawasaki A, et al. Long-term survival after resection of mass-forming type intrahepatic cholangiocarcinoma directly infiltrating the transverse colon and sequential brain metastasis: report of a case. Surg Today 2011; 41: 1410\u20133.","DOI":"10.1007\/s00595-010-4500-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Xie P, Guo L, Zhang B, et al. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Front Oncol 2022; 12: 911202.","DOI":"10.3389\/fonc.2022.911202"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30: 419\u201325.","DOI":"10.1200\/JCO.2011.38.0527"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8\u201310.","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Morino K, Seo S, Yoh T, et al. Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol 2020; 27: 1908\u201317.","DOI":"10.1245\/s10434-020-08207-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Brenner AW, Patel AJ. Review of current principles of the diagnosis and management of brain metastases. Front Oncol 2022; 12: 857622.","DOI":"10.3389\/fonc.2022.857622"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824\u201335.","DOI":"10.1056\/NEJMoa1709030"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021; 385: 683\u201394.","DOI":"10.1056\/NEJMc2115204"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Frega G, Cossio FP, Banales JM, et al. Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis. Cells 2023; 12: 2098.","DOI":"10.3390\/cells12162098"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Cottrell TR, Taube JM. PD-L1 and emerging biomarkers in immune checkpoint blockade therapy. Cancer J 2018; 24: 41\u20136.","DOI":"10.1097\/PPO.0000000000000301"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21: 671\u201384.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in <i>IDH1<\/i>-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 796\u2013807.","DOI":"10.1016\/S1470-2045(20)30157-1"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0620\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:46:41Z","timestamp":1768020401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0620\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0620","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0620"}}